"This is a waiting game"
Radio Feature 68: James Montier in conversation with Sona Blessing
Wednesday, March 20, 2013
James Montier is a member of GMO's Asset Allocation team. Prior to joining GMO in 2009, he was co-head of Global Strategy at Société Généralé. He has authored several books including "Behavioural Investing: A Practitioner's Guide to Applying Behavioural Finance; Value Investing: Tools and Techniques for Intelligent Investment"; and "The Little Book of Behavioural Investing". James is a visiting fellow at the University of Durham and a fellow of the Royal Society of Arts.
In this podcast he talks us through amongst others why in many ways he thinks this is the most difficult opportunity set an investor can face ...
Download this feature as MP3 (7.08 MB)
Listen to the complete feature
"This is a waiting game"
Or listen to selected sub-features
Asset allocation "when the Fed spikes the punch bowl".
Thoughts on the opportunity set within commodities?
Identifying investment opportunities now: where and which might they be?
What in your view are likely exogenous shock factors and what could be in the short term, some of the opportunities they would lead to?
What makes this particular investment environment so challenging?
The rationale for adjusting equity exposure allocations in the context of financial repression; and the role that dividend yields play in raising equity exposure.
Opalesque Exclusive: Despite bumpy June/July, CTAs hold on [more]
Bailey McCann, Opalesque New York: To say that things have been rocky in managed futures recently is putting it mildly. In June, the industry saw its worst month on a performance basis in the past four years. Then yesterday, Other Voices: Same day reporting and the evolving role of fund administrators [more]
By: Scott Price, Head of Business Development and Client Management for North America, Maitland
Ernst & Young’s latest glob Activist News - Celgene says patent-fighting hedge fund manager wants to short its shares [more]
From Reuters.com: Celgene Corp, one of the world's largest biotechnology companies, has accused U.S. hedge fund manager Kyle Bass of attempting to profit from his attempts to wipe out several major drug patents through his Coalition for Affordable Drugs.
The company asked the U.S. Patent and T Einhorn's Greenlight Capital hedge fund slumps 6.1 percent in July [more]
From Reuters/Thefiscaltimes.com: Hedge fund mogul David Einhorn's Greenlight Capital slumped 6.1 percent in July and is now down 9 percent for the year after gold, one of the fund's top holdings, tumbled to five-year lows last week.
Greenlight notified clients of its returns late on Friday, ac Cowen Group, Inc. to acquire Conifer Securities [more]
Cowen Group, Inc. and Conifer Securities, LLC had announced the signing of a definitive agreement under which Cowen will acquire Conifer Securities, the prime services division of Conifer Financial Services LLC. The transaction, the terms of which have not yet been disclosed, was approved by the boa